Brolucizumab
CAS 1531589-02-0 1 FDA-DMF supplierBiologic
Overview
Brolucizumab is a monoclonal single-chain variable fragment (scFv) targeting vascular endothelial growth factor A (VEGF-A). It is used in the treatment of neovascular (wet) age-related macular degeneration.
Therapeutic areas
Ophthalmology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.